An array of AI-powered features and automated tools may lead to improved workflow and image quality with the Voluson Expert 22, 20 and 18 ultrasound systems.
The Food and Drug Administration (FDA) has granted 510(k) clearance for artificial intelligence (AI) updates to the Voluson Expert Series of ultrasound systems geared toward examination of women with high-risk pregnancies.
New AI-enabled features with the Voluson Expert 22, 20 and 18 ultrasound systems include SonoLystlive, which facilitates increased accuracy for 11 to 14-week anatomical exams, and Graphicflow, which offers real-time visualization of blood flow trajectory that aids in detecting abnormal hemodynamics, according to GE HealthCare, the manufacturer of the Voluson Expert ultrasound platforms.
New artificial intelligence (AI) updates to the Voluson Expert 22, 20 and 18 ultrasound systems have garnered 510(k) clearance from the FDA. (Image courtesy of GE HealthCare.)
The company said other benefits include live C-plane tracking and automated plane alignment with SonoPelvicFloor3.0, which reportedly decreases exam time for pelvic floor measurement by 80 percent.
“We are proud to introduce these updates to the Voluson Expert ultrasound systems, which represent our ongoing commitment to advancing technology that addresses women's health needs of today, and the future,” noted Gerald Seifriedsberger, the general manager for Women’s Health, Advanced Visualization Solutions at GE HealthCare. “By introducing solutions that offer unparalleled clarity and detail, we can empower users with critical insights for informed care decisions and efficient exams, transforming how clinicians approach health care.”
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
Ultrasound-Guided Thermal Ablation Shows Low Recurrence of Thyroid Carcinoma at Five Years
June 16th 2025In a meta-analysis involving over 2,200 patients with T1NoMo papillary thyroid carcinoma, researchers noted 2 percent recurrence and no cases of lymph node metastasis five years after ultrasound-guided thermal ablation.